RET and non-small cell lung carcinoma: The advent of precision medicine has revolutionized the therapeutic landscape of NSCLC, and targeted therapies have been investigated in many clinical studies against patients with RET fusion-positive NSCLC, which includes multi-kinase inhibitors (MKIs) and selective RET inhibitors (Choudhury and Drilon 2020).